Pfizer doubles down on gene therapy pipeline with $70M Sangamo buy-in – FierceBiotech
FierceBiotech |
Pfizer doubles down on gene therapy pipeline with $70M Sangamo buy-in
FierceBiotech After deals and acquisitions with Spark Therapeutics and Bamboo, Pfizer is once again looking to bolster its rare and gene therapy pipeline as it outlines a new drug pact with Sangamo. The collaboration license agreement focuses on the development and … Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal Pfizer and Sangamo ink a $545M hemophilia-gene therapy deal Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy |
